Gsa Capital Partners LLP Kal Vista Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$9.85 - $16.83 $210,927 - $360,397	-21,414 Reduced 55.4%	17,236 $250,000
Q2 2022 Aug 09, 2022	BUY	$8.16 - $15.1 $123,607 - $228,734	15,148 Added 64.45%	38,650 $380,000
Q1 2022 May 11, 2022	BUY	$11.2 - $16.97 $134,433 - $203,690	12,003 Added 104.38%	23,502 $346,000
Q4 2021 Feb 14, 2022	BUY	$12.36 - $18.28 $142,127 - $210,201	11,499 New	11,499 $152,000
Q1 2021 May 10, 2021	SELL	$14.69 - $42.57 $332,934 - $964,806	-22,664 Closed	0 $0
Q4 2020 Feb 03, 2021	SELL	$12.88 - $19.47 $36,089 - $54,554	-2,802 Reduced 11.0%	22,664 $430,000
Q3 2020 Nov 06, 2020	BUY	$9.83 - $13.99 $250,330 - $356,269	25,466 New	25,466 $321,000
Q2 2020 Aug 11, 2020	SELL	$6.75 - $12.89 $113,305 - $216,371	-16,786 Closed	0 $0
Q1 2020 May 12, 2020	SELL	$5.8 - $18.56 $290 - $927	-50 Reduced 0.3%	16,786 $128,000
Q4 2019 Feb 12, 2020	BUY	$10.31 - $17.81 $67,169 - $116,032	6,515 Added 63.12%	16,836 $300,000
Q3 2019 Nov 12, 2019	BUY	$11.6 - $21.67 $119,723 - $223,656	10,321 New	10,321 $120,000
Q2 2019 Aug 06, 2019	SELL	$18.44 - $30.89 $135,921 - $227,690	-7,371 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$16.51 - $31.1 $121,695 - $229,238	7,371 New	7,371 $211,000

126

47.9M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $204M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.